Form 4: Alto Neuroscience Director Acquires Stock Options in Lieu of Retainer Fees

Christopher Nixon Cox, a director at Alto Neuroscience, acquired stock options for 25,236 shares in lieu of $80,000 in retainer fees.

Summary

• Christopher Nixon Cox, a director of Alto Neuroscience, Inc., filed a Form 4 disclosing a transaction on January 2, 2025.
• Cox acquired stock options for 25,236 shares of Alto Neuroscience common stock at an exercise price of $4.38.
• The options vest in four equal installments on March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025, contingent upon continuous service.
• These options were granted in lieu of $80,000 in retainer fees, according to the Issuer's Non-Employee Director Compensation Policy.
• The options expire on January 1, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of director compensation. The use of stock options instead of cash could be seen as slightly positive for the company's financial health.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• Using stock options in lieu of cash retainer fees can conserve the company's cash resources.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies continued service of the director through the end of 2025.

Industry Context

Director compensation through stock options is a common practice in the biotechnology industry, aligning the interests of directors with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a common practice across the biotech industry.
• Companies like Biogen and Amgen also use stock options as part of their director compensation packages.
• The vesting schedule of quarterly installments is fairly standard, aligning with typical director service periods.
• The amount of retainer fees replaced by the options ($80,000) is within the typical range for non-executive director compensation in similarly sized biotech companies.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning director interests with long-term company performance.
• The company benefits from conserving cash by issuing stock options instead of cash retainer fees.

Key Dates